La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Gan & Lee Pharmaceuticals Gestione

Gestione criteri di controllo 4/4

Gan & Lee Pharmaceuticals' Il CEO è Kai Du, nominato in Jul2020, ha un mandato di 4.08 anni. possiede direttamente 0.087% delle azioni della società, per un valore di CN¥ 22.32M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.1 anni e 4.4 anni.

Informazioni chiave

Kai Du

Amministratore delegato

CN¥1.0m

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	4.2yrs
Proprietà del CEO	0.09%
Durata media del management	4.2yrs
Durata media del Consiglio di amministrazione	4.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Kai Du (47 yo)

4.2yrs

Mandato

CN¥1,041,900

Compensazione

Mr. Kai Du is General Manager of Gan & Lee Pharmaceuticals. since July 20, 2020 and has been its Director since April 26, 2019.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Gan Zhongru	Founder & Chairman	26.7yrs	CN¥457.20k	35.48% CN¥ 9.0b
Kai Du	GM & Director	4.2yrs	CN¥1.04m	0.087% CN¥ 22.0m
Cheng Sun	CFO & Deputy GM	4.2yrs	CN¥695.20k	0.022% CN¥ 5.5m
Wei Chen	Deputy GM & Director	less than a year	CN¥892.20k	0.087% CN¥ 22.0m
Weiqiang Song	Deputy GM & Director	8.7yrs	CN¥960.50k	0.087% CN¥ 22.0m
Rong Zou	Secretary	6.8yrs	CN¥695.00k	0.087% CN¥ 22.0m
Cheng Xing	Deputy General Manager	4.2yrs	CN¥752.80k	0.087% CN¥ 22.0m
Zifei Yuan	Deputy General Manager	4.2yrs	CN¥710.50k	0.087% CN¥ 22.0m
Zhi Li	Deputy General Manager	less than a year	Nessun dato	Nessun dato

4.2yrs

Durata media

42yo

Età media

Gestione esperta: Il team dirigenziale di 603087 è considerato esperto (durata media dell'incarico 4.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Gan Zhongru	Founder & Chairman	26.7yrs	CN¥457.20k	35.48% CN¥ 9.0b
Kai Du	GM & Director	5.4yrs	CN¥1.04m	0.087% CN¥ 22.0m
Wei Chen	Deputy GM & Director	3yrs	CN¥892.20k	0.087% CN¥ 22.0m
Weiqiang Song	Deputy GM & Director	9yrs	CN¥960.50k	0.087% CN¥ 22.0m
Jiao Jiao	Director	3.5yrs	CN¥1.04m	0.045% CN¥ 11.4m
Lei Yin	Director	3.5yrs	CN¥897.10k	0.020% CN¥ 5.1m
Yanqing He	Independent Director	5.4yrs	CN¥72.00k	Nessun dato
Guojun Zheng	Independent Director	5.4yrs	CN¥72.00k	Nessun dato
Yi Wang	Supervisor	3.5yrs	Nessun dato	Nessun dato
Tao Zhang	Chairman of the Board of Supervisors	3yrs	Nessun dato	Nessun dato
Jiaxin Wang	Supervisor	5.4yrs	Nessun dato	Nessun dato
Zengyi Chang	Independent Director	2.3yrs	CN¥72.00k	Nessun dato

4.5yrs

Durata media

44.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 603087 sono considerati esperti (durata media dell'incarico 4.4 anni).

Gan & Lee Pharmaceuticals Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Gan & Lee Pharmaceuticals., Annual General Meeting, May 16, 2024

Less than half of directors are independent

Recent updates

Gan & Lee Pharmaceuticals. (SHSE:603087) announces an Equity Buyback for CNY 300 million worth of its shares.

Second quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.15 in 2Q 2023)

Gan & Lee Pharmaceuticals. to Report First Half, 2024 Results on Aug 29, 2024

Gan & Lee Pharmaceuticals., Annual General Meeting, May 16, 2024

First quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.09 in 1Q 2023)

Gan & Lee Pharmaceuticals. to Report Q1, 2024 Results on Apr 25, 2024

Gan & Lee Pharmaceuticals. to Report Fiscal Year 2023 Results on Apr 25, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.39 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.55 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.09 (vs CN¥0.20 in 1Q 2022)

Gan & Lee Pharmaceuticals.(XSSC:603087) dropped from FTSE All-World Index (USD)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.39 loss per share (vs CN¥0.90 profit in 3Q 2021)

Gan & Lee Pharmaceuticals. announced that it expects to receive CNY 813.6 million in funding

Second quarter 2022 earnings released: CN¥0.55 loss per share (vs CN¥0.32 profit in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.34 in 1Q 2021)

Gan & Lee Pharmaceuticals Co., Ltd. Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18

Third quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.70 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.34 in 2Q 2020)

Gan & Lee Pharmaceuticals Co., Ltd. Announces Positive Phase 1 Clinical Trial Results at the 81st Scientific Sessions of the American Diabetes Association

First quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.24 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥2.31 (vs CN¥2.31 in FY 2019)

New 90-day low: CN¥121

FDA Grants Fast Track Designation for Gan & Lee Pharmaceuticals Co., Ltd.'s GLR2007, for the Treatment of Patients with Glioblastoma

Investor sentiment improved over the past week

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media